I am the UK Chief Investigator for this global translational study in breast cancer. Sponsored by Novartis, the study aims to recruit 2050 women with advanced breast cancer globally to assess their tumours for possible biomarkers predictive of response to targeted therapies. In addition to leading the study in the UK, I have also worked with Novartis and Professor Gonzalez de Castro to ensure that the Precision Medicine Centre can act as the central UK analytical laboratory for this study. Thus this study generates commercial income both for PMC and also for the NICTN within the Belfast Trust.